Oncology News

• ASCO 2023 CAR-T Hikes Overall Survival in Relapsed/Refractory LBCL CAR T-cell therapy drug axicabtagene ciloleucel significantly improved overall survival compared with standard second-line treatments in patients with early relapsed or refractory large B-cell lymphoma.
  MDedge News, June 09, 2023
• ASCO 2023 'Remarkable': CAR T Therapy for CLL/SLL CAR T-cell therapy showed efficacy in achieving complete responses among patients with relapsed or refractory CLL or SLL after BTKi and BCL2 inhibitor.
  MDedge News, June 09, 2023
• VA Study Finds Lower Racial Disparity in Melanoma Diagnoses The results might be explained by "all patients in the VA dataset having insured access to health care, regardless of socioeconomic status," the authors wrote.
  MDedge News, June 09, 2023
• Antibiotic Prophylaxis May Lower SSIs in Skin Cancer Surgery Microdose delivery of clindamycin reduced the rate of postoperative surgical site infections by almost two thirds; flucloxacillin, however, showed no significant benefit over the control.
  Medscape Medical News, June 09, 2023
• WHO Advises Against Nonsugar Sweeteners for Weight Control Replacing free sugars with nonsugar sweeteners does not help with weight control in the long-term, according to the World Health Organization.
  Medscape Medical News, June 09, 2023
• ASCO 2023 Multiprong Strategy Makes Clinical Trials Less White Clinical trials for cancer control and treatment typically have very few patients from non-White backgrounds, but a multipronged approached has increased participation of underrepresented patients.
  Medscape Medical News, June 09, 2023
• ASCO 2023 DEI Training Gives Oncology Fellows More Confidence After receiving diversity, equity, and inclusion (DEI) training, fellows at Yale's medical school say they felt more comfortable dealing with racial inequality and sexual harassment.
  Medscape Medical News, June 09, 2023
• Is ChatGPT a Friend or Foe of Medical Publishing? The popular AI chatbot has prompted journal editors to write new policies to address a wave of manuscripts that use ChatGPT and other tools like it.
  Medscape Medical News, June 08, 2023
• ASCO 2023 First or Second-Line CDK4/6 Inhibition in Breast Cancer? Patients with advanced ER+/HER2– breast cancer receiving first line CDK4/6 inhibitor therapy experienced no progression-free survival or overall survival advantages compared to second line therapy.
  MDedge News, June 08, 2023
• Sequencing Strategy in Ovarian Cancer Helps Guide Treatment A targeted genetic sequencing strategy effectively identified homologous recombination DNA repair deficiency in ovarian cancer patients, and may eventually help predict treatment response.
  MDedge News, June 08, 2023
• Metronomic Therapy Effective in Head and Neck Cancer In the second-line setting of head and neck cancer, metronomic triple therapy outperformed clinician choice chemotherapy in both progression-free survival and overall survival.
  MDedge News, June 08, 2023
• ASCO 2023 PMBCL: Postremission, Patients May Safely Skip Radiation Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy.
  MDedge News, June 08, 2023
• Widespread Carboplatin, Cisplatin Shortages: NCCN Survey A new NCCN survey found that most centers are experiencing shortages of carboplatin and cisplatin. The NCCN has called for strategies to address these drug shortages.
  Medscape Medical News, June 08, 2023
• Palliative Care Laws Make a Difference for Cancer Patients State-level palliative care laws ― particularly prescriptive laws ― have a measurable effect on the likelihood of patients with cancer dying at home or in hospice care.
  Medscape Medical News, June 08, 2023
• Cognitive Decline Risk in Adult Childhood Cancer Survivors All cancers survivors, regardless of therapy, should be regularly screened for new-onset neurocognitive problems "decades" after diagnosis, researchers say.
  Medscape Medical News, June 07, 2023
• Risk of Falls With Newer Antiandrogens for Prostate Cancer Second-generation antiandrogens for prostate cancer carry a substantial risk of cognitive problems and fatigue, and they increase the risk of falls by 87%, warn researchers.
  Medscape Medical News, June 07, 2023
• ASCO 2023 Huge Underuse of Germline Testing for Cancer Patients Rates of germline genetic testing for patients newly diagnosed with common cancers are far below recommended levels, prompting calls for innovative solutions.
  Medscape Medical News, June 07, 2023
• ASCO 2023 CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.
  Medscape Medical News, June 06, 2023
• ASCO 2023 T-DXd Active in Many Solid Tumors; 'Shift in Thinking' The antibody-drug conjugate trastuzumab-deruxtecan was associated with high objective response rates among patients with a range of HER2-expressing solid tumors.
  Medscape Medical News, June 06, 2023
• ASCO 2023 Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer A large review has found no difference in overall survival with fixed-duration vs ongoing ICI treatment in progression-free non–small cell lung cancer.
  Medscape Medical News, June 06, 2023